相关临床试验
0
0 进行中
药物批准
494
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
• Camber Pharmaceuticals has announced the launch of Temozolomide Capsules, USP, an alkylating drug used in the treatment of glioblastoma and anaplastic astrocytoma in adults. • The medication will be available in five different strengths (5mg, 20mg, 100mg, 140mg, 180mg, and 250mg) and in various count options to support different treatment regimens. • Temozolomide is primarily used as a concurrent treatment with radiotherapy for newly diagnosed glioblastoma patients, followed by maintenance therapy, addressing critical needs in brain cancer treatment.
- Camber Pharmaceuticals has launched the first AB-rated generic version of eltrombopag (Promacta), offering a more affordable treatment option for patients with thrombocytopenia and aplastic anemia. - The generic eltrombopag is available as both oral suspension and tablets in multiple dosage strengths, with a copay assistance program that could allow eligible patients to receive the medication at no out-of-pocket cost. - This development addresses significant cost barriers that have limited access to this life-saving thrombopoietin receptor agonist, which stimulates platelet production in patients with severe aplastic anemia and immune thrombocytopenia.
• Camber Pharmaceuticals has successfully implemented comprehensive DSCSA compliance measures, achieving 100% aggregation from bottle to pallet level for pharmaceutical product tracking. • The company has demonstrated exceptional performance in customer testing with 95-100% success rates, utilizing TraceLink's Verification Routing Services for product authentication since 2022. • In preparation for the November 2024 DSCSA deadline, Camber is increasing inventory levels to support customers whose other suppliers may not achieve full compliance.
